Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Promacta

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Novartis legal head resigns over Cohen payments

General counsel steps down, but Novartis still facing difficult questions

- PMLiVE

Daily Brief

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Novartis launches remote clinical trial app

FocalView will allow patients to participate in ophthalmology trials

- PMLiVE

Sobi poaches Pfizer’s Fredrick Wetterlundh

He joins the speciality healthcare group as head of human resources

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

Can value-based healthcare take off and reach for the skies?

Are companies willing to contribute to the change in the healthcare system?

- PMLiVE

Novartis pushes ‘virtual’ clinical trial concept

Teams up with Science 37 to run ten digital-based trials over the next three years

Novartis telemedicine service to be ramped up in Ghana

Country's health service selects it as part of the national eHealth strategy

- PMLiVE

FDA hands GSK a reprieve by blocking Novartis generic

The Advair rival could be delayed until 2019

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links